[go: up one dir, main page]

WO2001019358A3 - Use dexrazoxane for treating psoriasis - Google Patents

Use dexrazoxane for treating psoriasis Download PDF

Info

Publication number
WO2001019358A3
WO2001019358A3 PCT/EP2000/008879 EP0008879W WO0119358A3 WO 2001019358 A3 WO2001019358 A3 WO 2001019358A3 EP 0008879 W EP0008879 W EP 0008879W WO 0119358 A3 WO0119358 A3 WO 0119358A3
Authority
WO
WIPO (PCT)
Prior art keywords
dexrazoxane
treating psoriasis
psoriasis
treating
dioxopiperazin
Prior art date
Application number
PCT/EP2000/008879
Other languages
French (fr)
Other versions
WO2001019358A2 (en
Inventor
Iervant Zarmanian
Jadranka Rogan-Grgas
Original Assignee
Cyathus Exquirere Pharmaforsch
Iervant Zarmanian
Rogan Grgas Jadranka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/070,687 priority Critical patent/US6693100B1/en
Priority to KR1020027003049A priority patent/KR20020035131A/en
Priority to BR0013921-1A priority patent/BR0013921A/en
Priority to HU0202791A priority patent/HUP0202791A3/en
Priority to SK280-2002A priority patent/SK2802002A3/en
Priority to PL00354980A priority patent/PL354980A1/en
Priority to EP00960646A priority patent/EP1214073A2/en
Priority to EEP200200128A priority patent/EE04871B1/en
Application filed by Cyathus Exquirere Pharmaforsch, Iervant Zarmanian, Rogan Grgas Jadranka filed Critical Cyathus Exquirere Pharmaforsch
Priority to MXPA02002486A priority patent/MXPA02002486A/en
Priority to CA002384685A priority patent/CA2384685A1/en
Priority to AU72865/00A priority patent/AU7286500A/en
Publication of WO2001019358A2 publication Critical patent/WO2001019358A2/en
Publication of WO2001019358A3 publication Critical patent/WO2001019358A3/en
Priority to BG106428A priority patent/BG106428A/en
Priority to HR20020201A priority patent/HRPK20020201B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The use for the manufacture of a medicament for treating psoriasis of dexrazoxane, the d-isomer of 1,2-bis(3,5-dioxopiperazin-1-yl)-propane, or a physiologically acceptable salt thereof.
PCT/EP2000/008879 1999-09-10 2000-09-08 Use dexrazoxane for treating psoriasis WO2001019358A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
EP00960646A EP1214073A2 (en) 1999-09-10 2000-09-08 Use of dexrazoxane for treating psoriasis
BR0013921-1A BR0013921A (en) 1999-09-10 2000-09-08 Pharmaceutical compositions for the treatment of psoriasis
HU0202791A HUP0202791A3 (en) 1999-09-10 2000-09-08 Pharmaceutical compositions for treating psoriasis
SK280-2002A SK2802002A3 (en) 1999-09-10 2000-09-08 The use of dexrazoxane, an article comprising dexrazoxane, method for treating psoriasis and method for producing a drug
PL00354980A PL354980A1 (en) 1999-09-10 2000-09-08 Use dexrazoxane for treating psoriasis
EEP200200128A EE04871B1 (en) 1999-09-10 2000-09-08 The use of dextrasoxane, a product and a method for the manufacture of a medicament for the treatment of psoriasis
MXPA02002486A MXPA02002486A (en) 1999-09-10 2000-09-08 Use dexrazoxane for treating psoriasis.
US10/070,687 US6693100B1 (en) 1999-09-10 2000-09-08 Pharmaceutical compositions for treating psoriasis
KR1020027003049A KR20020035131A (en) 1999-09-10 2000-09-08 Use dexrazoxane for treating psoriasis
CA002384685A CA2384685A1 (en) 1999-09-10 2000-09-08 Use dexrazoxane for treating psoriasis
AU72865/00A AU7286500A (en) 1999-09-10 2000-09-08 Pharmaceutical compositions for treating psoriasis
BG106428A BG106428A (en) 1999-09-10 2002-02-22 Pharmaceutical compositions for treating psoriasis
HR20020201A HRPK20020201B1 (en) 1999-09-10 2002-03-05 Pharmaceutical compositions for treating psoriasis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AT155899 1999-09-10
ATA1558/99 1999-09-10
US18380600P 2000-02-22 2000-02-22
US60/183,806 2000-02-22

Publications (2)

Publication Number Publication Date
WO2001019358A2 WO2001019358A2 (en) 2001-03-22
WO2001019358A3 true WO2001019358A3 (en) 2001-10-04

Family

ID=25596169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/008879 WO2001019358A2 (en) 1999-09-10 2000-09-08 Use dexrazoxane for treating psoriasis

Country Status (16)

Country Link
EP (1) EP1214073A2 (en)
KR (1) KR20020035131A (en)
CN (1) CN1378451A (en)
AU (1) AU7286500A (en)
BG (1) BG106428A (en)
BR (1) BR0013921A (en)
CA (1) CA2384685A1 (en)
CZ (1) CZ2002729A3 (en)
EE (1) EE04871B1 (en)
HR (1) HRPK20020201B1 (en)
HU (1) HUP0202791A3 (en)
MX (1) MXPA02002486A (en)
PL (1) PL354980A1 (en)
RU (1) RU2002106874A (en)
SK (1) SK2802002A3 (en)
WO (1) WO2001019358A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021053523A1 (en) * 2019-09-18 2021-03-25 Tryp Therapeutics Compositions and methods to improve the therapeutic benefit of bis-dioxopiperazines
JPWO2023182298A1 (en) 2022-03-22 2023-09-28

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941790A (en) * 1967-07-03 1976-03-02 National Research Development Corporation Bis diketopiperazines
US4275063A (en) * 1967-07-03 1981-06-23 National Research Development Corporation Pharmaceutical compositions
EP0330381A1 (en) * 1988-02-17 1989-08-30 Erbamont, Inc. Process for preparing bis (3,5-dioxopiperazinyl) alkanes or alkenes
WO1995003054A1 (en) * 1993-07-23 1995-02-02 Lxr Biotechnology Inc. Methods of treating apoptosis and associated conditions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941790A (en) * 1967-07-03 1976-03-02 National Research Development Corporation Bis diketopiperazines
US4275063A (en) * 1967-07-03 1981-06-23 National Research Development Corporation Pharmaceutical compositions
EP0330381A1 (en) * 1988-02-17 1989-08-30 Erbamont, Inc. Process for preparing bis (3,5-dioxopiperazinyl) alkanes or alkenes
WO1995003054A1 (en) * 1993-07-23 1995-02-02 Lxr Biotechnology Inc. Methods of treating apoptosis and associated conditions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ATHERTON D.J. ET AL: "Razoxane (ICRF 159) in psoriasis.", LANCET, (1976) 2/7998 (1296). CODEN: LANCAO, XP000991316 *
ATHERTON D.J. ET AL: "Razoxane (ICRF 159) in the treatment of psoriasis.", BRITISH JOURNAL OF DERMATOLOGY, (1980) 102/3 (307-317). CODEN: BJDEAZ, XP000991409 *
HORTON J.J. ET AL: "Long-term razoxane therapy of psoriasis.", BRITISH JOURNAL OF DERMATOLOGY, (1983) 109/SUPPL. 24 (26). CODEN: BJDEAZ, XP000992104 *
MOM A. ET AL: "Razoxane in the treatment of psoriatic patients resistant to or intolerant of PUVA, methotrexate and etretinate.", ACTA DERMATO-VENEREOLOGICA, (1982) 62/4 (357-358). CODEN: ADVEA4, XP000991451 *
VON HOFF D D: "Phase I trials of dexrazoxane and other potential applications for the agent.", SEMINARS IN ONCOLOGY, (1998 AUG) 25 (4 SUPPL 10) 31-6. REF: 51, XP000991547 *

Also Published As

Publication number Publication date
EE04871B1 (en) 2007-08-15
BR0013921A (en) 2002-05-14
WO2001019358A2 (en) 2001-03-22
MXPA02002486A (en) 2004-09-10
HUP0202791A3 (en) 2003-02-28
CZ2002729A3 (en) 2002-07-17
CN1378451A (en) 2002-11-06
HUP0202791A2 (en) 2003-01-28
BG106428A (en) 2003-04-30
HRPK20020201B1 (en) 2004-08-31
CA2384685A1 (en) 2001-03-22
EP1214073A2 (en) 2002-06-19
KR20020035131A (en) 2002-05-09
EE200200128A (en) 2003-04-15
RU2002106874A (en) 2003-11-20
SK2802002A3 (en) 2003-02-04
AU7286500A (en) 2001-04-17
PL354980A1 (en) 2004-03-22
HRP20020201A2 (en) 2003-06-30

Similar Documents

Publication Publication Date Title
DE50008336D1 (en) MULTILAYER TABLET FOR THE ADMINISTRATION OF A FIXED COMBINATION OF TRAMADOL AND DICLOFENAC
EP1020461A3 (en) Use of alkaline salts of the (-)-enantiomer of omeprazole
WO2003009838A1 (en) Use of stilbene compounds in preparing medicaments for treating or preventing diabetes and diseases associated with retrovirus
LU91172I2 (en) Melagatran, the stereoisomers thereof, and the physiologically acceptable salts thereof (m elagatran astrazeneca).
CA2386690A1 (en) Pharmaceutical tramadol salts
MX9602683A (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutically active substances.
HUP9600924A2 (en) Aromatic hydroxamic acid derivatives, their production, use and pharmaceutical compn. contg. the said compds.
HK1048986A1 (en) 2'-Substituted 1,1'-iphenyl-2-carbonamides, methodfor the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds.
AU6682298A (en) Use of r-nsaid's for the prevention of alzheimer's disease
ZA988095B (en) New peptide mimetics for the treatment of bone metabolic disorders, methods for their production, and drugs containing these compounds.
EP1440691A3 (en) Treatment of neurotic disorders
ZA200200222B (en) Titanium derived compounds, preparation and use thereof.
AU2002222689A1 (en) Titanium compound, aqueous solution containing titanium, and process for producing the same
CA2379314A1 (en) Tablet for sucking, containing ambroxol
EP0601909A3 (en) Dibekacin derivatives and arbekacin derivatives active against resistant bacteria, and the production thereof.
CA2399709A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
WO2001041709A3 (en) Methods for treating cell death diseases and inflammation
WO2001019358A3 (en) Use dexrazoxane for treating psoriasis
CA2320627A1 (en) Medicament for treatment of diastolic dysfunction
YU17002A (en) Dextrazohane use in psoriasis healing
ZA9711719B (en) Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis.
BG106534A (en) Oral solution containing galanthamine and a sweetening agent
HUP9601701A2 (en) Aromatic hydroxamic acid compounds, process for producing them and their use pharmaceutical compns. contg. them and process for producing the said compds.
CA2349719A1 (en) Controlled delivery of antidepressants
ZA200104304B (en) Carbamate derivatives of diaryl 1,3,4-oxadiazolone.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-170/02

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2000 106428

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2802002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PV2002-729

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PK20020201A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/002486

Country of ref document: MX

Ref document number: 1020027003049

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 008126828

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2384685

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2002 2002106874

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000960646

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027003049

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10070687

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000960646

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-729

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000960646

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020027003049

Country of ref document: KR